Drug Profile

TAK 285

Alternative Names: TAK-285

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Takeda
Class Antineoplastics
Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Cancer; Solid tumours

Most Recent Events

03 Feb 2011 Discontinued - Phase-I for Cancer in USA (PO)
03 Feb 2011 Discontinued - Phase-I for Solid tumours in Japan (PO)
14 Dec 2008 Pharmacodynamics data from a preclinical study in breast cancer presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS-2008)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com